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CASE PRESENTATION
Patient 1
A 57-year-old man was diagnosed with AL amyloidosis
after presenting with nephrotic syndrome. He had been
well until 6 months earlier, when he noticed intermit-
tent ankle swelling. He sought medical attention approx-
imately 2 months later because of increased swelling of
his legs and progressive fatigue.
At that time, his urinary protein excretion was 7.4 g/day.
Serum creatinine was 0.9 mg/dL and serum albumin
3.1 g/dL. A renal biopsy disclosed amorphous material
in the mesangium that was birefringent under polarized
light when stained with Congo red dye. Immunofluores-
cence was positive for lambda light chain in the glomeru-
lar capillary walls, mesangium, and tubulointerstitium.
Electron microscopy revealed randomly dispersed fib-
rils with a diameter of 10 nm throughout the mesangium
and interstitium. A monoclonal IgG lambda protein and
a monoclonal free lambda light chain were evident by
immunofixation electrophoresis (IFE) of the serum and
urine, respectively. Bone marrow biopsy had 5% plasma
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cells with lambda light chain predominance. Additional
clinical evaluation was remarkable for orthostatic hy-
potension and hepatomegaly. Alkaline phosphatase was
480 U/L; other liver enzymes were normal. An electro-
cardiogram showed normal voltage, and ventricular wall
thickness was normal by echocardiography.
Three months later, the patient underwent treatment
with high-dose intravenous melphalan (200 mg/m2) and
autologous peripheral blood stem cell transplantation.
Just prior to treatment, the urinary protein excretion
was 10 g/day and serum creatinine 1.3 mg/dL. The peri-
transplant course was notable for anasarca, mucositis, a
transient increase in serum creatinine to 3.2 mg/dL, and
a neutropenic fever. Six months after treatment, a bone
marrow biopsy showed fewer than 5% plasma cells with
no light chain isotype predominance. The monoclonal im-
munoglobulin protein was no longer evident by serum or
urine IFE. Together, these findings suggested a hemato-
logic remission, and annual evaluations during the sub-
sequent 4 years have shown no evidence of a recurrence
of the plasma cell dyscrasia. Urinary protein excretion
decreased progressively to 3.0 g/day, 1.1 g/day, 0.7 g/day,
and 0.3 g/day at years 1, 2, 3, and 4, respectively. Serum
creatinine concentration has fluctuated between 1.0 and
1.3 mg/dL during the 4 years following treatment. Serum
alkaline phosphatase was 170 U/mL at the most recent
visit, and hepatomegaly was no longer appreciable by
physical examination.
Patient 2
A 42-year-old woman with a family history of amy-
loidosis was evaluated after amyloid was identified in
a duodenal biopsy specimen. The patient’s mother had
systemic amyloidosis due to a mutation in transthyretin
(TTR) that resulted in a substitution of methionine for
valine at amino acid position 30 (Val30Met). The dis-
ease manifestations in the mother included sensorimotor
neuropathy, autonomic neuropathy, cardiac disease, and
subnephrotic-range proteinuria. The mother’s symptoms
began at approximately 40 years of age, and she died in
1980 at age 53.
The patient (that is, the daughter) was found to have
subnephrotic-range proteinuria one year earlier and
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Table 1. Types of amyloidosis
Disease Precursor protein Amyloid protein Organ involvement
Systemic forms
AL amyloidosis Immunoglobulin light chain AL Kidney, heart, liver, GI tract,
spleen, nervous system, soft
tissue, thyroid, adrenals
AA amyloidosis Serum amyloid A (SAA) AA Kidney, liver, GI tract, spleen,
autonomic nervous system,
thyroid
Familial amyloidosis Transthyretin, apolipoprotein AI,
apolipoprotein AII, fibrinogen
Aa chain, lysozyme, gelsolin,
cystatin C
ATTR, AApoAI, AApoAII,
AFibA, ALys, AGel, ACys
Varies with amyloid protein and
mutation. Kidney affected in
TTR, ApoAI, Apo AII, FibAa,
and Lys disease
Senile systemic amyloidosis Transthyretin (wild-type) ATTR Heart, soft tissue
Dialysis-related amyloidosis Beta-2 microglobulin Ab2M Periarticular tissue, bone
Localized forms
Localized AL Immunoglobulin light chain AL Tracheobronchial tree, bladder,
ureter
Alzheimer’s disease Ab protein precursor Ab Brain
Creutzfeldt-Jakob disease Prion protein APrP Brain
Type 2 diabetes mellitus Islet amyloid polypeptide AIAPP Pancreas
underwent abdominal fat aspiration that was negative
for amyloid by Congo red staining. Upper endoscopy was
performed because of vitamin D deficiency, and amyloid
was present in the duodenal biopsy specimen obtained
during the procedure. The patient felt well and had no
symptoms other than supraventricular tachycardia that
began shortly after the birth of her fourth child and was
controlled with atenolol. Physical examination that in-
cluded a detailed evaluation by a neurologist was unre-
markable. Electrocardiogram revealed left anterior fas-
cicular block with normal voltage. Echocardiography dis-
closed that wall thickness, valves, and ventricular function
all were normal. Serum creatinine was 1.0 mg/dL, and
a 24-hour urine collection contained 1.8 g protein. Iso-
electric focusing studies of the serum revealed abnormal
migration of TTR protein, and subsequent DNA studies
disclosed the presence of a Val30Met TTR mutation. At
present, the patient is being followed closely in anticipa-
tion of orthotopic liver transplantation when the mani-
festations of amyloidosis become more pronounced.
DISCUSSION
DR. LAURA M. DEMBER (Associate Professor of
Medicine, Renal Section, and Renal Section and Amy-
loid Treatment and Research Program, Boston Univer-
sity School of Medicine, Boston, Massachusetts): These
cases describe two patients with systemic amyloidosis.
Patient 1 has amyloid light chain (AL) amyloidosis, and
Patient 2 has familial amyloidosis of the TTR type. The
patient with AL amyloidosis underwent treatment with
high-dose chemotherapy and autologous stem cell trans-
plantation, and the patient with TTR amyloidosis is being
followed closely in anticipation of future orthotopic liver
transplantation. Although these treatment approaches
appear to be quite different, they are similar in that they
both target the source of the amyloidogenic protein. In
AL amyloidosis, the source of the amyloidogenic protein
is clonal plasma cells in the bone marrow, and in familial
TTR amyloidosis, the source is the liver. In addition, both
treatments are aggressive approaches that have substan-
tial toxicity but offer the possibility of fully eliminating
new amyloid production.
Targeting the source of the amyloidogenic protein has
been the most widely employed and most successful treat-
ment approach for the systemic amyloidoses to date.
However, with advances in the understanding of the pro-
cesses involved in amyloid fibril formation and tissue de-
position, treatments directed at other targets are being
developed, and some are being tested in clinical trials.
This Nephrology Forum will focus on current and emerg-
ing approaches for the treatment of the systemic amy-
loidoses. My discussion of treatment will be organized
around the therapeutic targets rather than the specific
type of amyloidosis.
Classification and clinical features
The amyloidoses are a group of diseases in which pro-
teins that are normally soluble deposit extracellularly in
tissues as insoluble fibrils. The fibrils have a character-
istic beta-pleated sheet configuration that renders them
avid for Congo red dye. Classification of the amyloidoses
is based on the precursor proteins that form the amy-
loid fibrils, and the distribution of amyloid deposition
as either systemic or localized (Table 1) [1]. In systemic
amyloidosis, the amyloidogenic protein is produced at a
site distant from the sites of deposition. In contrast, in
localized forms (for example, Alzheimer’s disease), the
amyloid deposition occurs at the site of production of the
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amyloidogenic protein. Here we will focus on the sys-
temic amyloidoses.
AL amyloidosis
AL amyloidosis, the most common of the systemic
amyloidoses, reportedly affects 5 to 12 persons/million/
year, although autopsy studies suggest that the actual in-
cidence might be higher [2]. The amyloidogenic protein
in AL amyloidosis is an immunoglobulin light chain or
light chain fragment produced by clonal plasma cells in
the bone marrow. The plasma cell burden is usually low
and typically comprises 5% to 10% of the cells in the
bone marrow [3]. However, approximately 10% to 15%
of patients with AL amyloidosis have associated multiple
myeloma [4].
In AL disease, amyloid deposition can occur in any or-
gan except for the central nervous system. The organs
most frequently involved are the kidney and the heart [4,
5]. Kidney involvement usually manifests as nephrotic
syndrome and progressive impairment of renal function.
Not all patients with renal involvement have protein-
uria. Amyloid deposition that is restricted to the renal
vasculature or tubulointerstitium reduces the glomeru-
lar filtration rate but causes minimal proteinuria. Amy-
loid deposition in the myocardium results in a restrictive
cardiomyopathy. The left-ventricular wall is concentri-
cally thickened with normal or reduced cavity size. The
ventricular ejection fraction can be normal or only mod-
estly decreased despite substantial amyloid infiltration,
but impaired ventricular filling limits cardiac output [6].
Low voltage on the electrocardiogram is often present
and reflects the infiltrative, rather than a hypertrophic,
basis for the ventricular wall thickening. Liver involve-
ment produces hepatomegaly that can be massive. Ele-
vation in alkaline phosphatase with only a mild elevation
in transaminases is characteristic of hepatic amyloidosis,
in which infiltration of the sinusoids rather than direct
hepatocyte injury occurs [7]. Autonomic nervous system
disease can produce severe orthostatic hypotension and
early satiety from delayed gastric emptying. Symmetric
sensory neuropathy that progresses in a distal to proxi-
mal pattern is the usual manifestation of peripheral ner-
vous system involvement. Soft tissue amyloid deposition
produces carpal tunnel syndrome, skin nodules, periar-
ticular infiltration, alopecia, nail dystrophy, macroglos-
sia, submandibular gland enlargement, and hoarseness.
Macroglossia is extremely rare in the non-AL amyloi-
doses. Other sites of amyloid deposition in AL disease
include the lung, pleura, thyroid gland, and adrenal glands
[4, 8].
The rate of disease progression is variable and depends
somewhat on organ involvement. Overall survival in se-
ries published in the 1990s is approximately 12 to 24
months. Patients with clinically evident cardiac involve-
ment have a median survival of approximately 6 months
[4, 9–11].
AA amyloidosis
AA amyloidosis, also referred to as secondary amyloi-
dosis, occurs in the setting of chronic inflammatory con-
ditions. The amyloidogenic precursor protein is serum
amyloid A (SAA), an acute-phase reactant synthesized
by the liver. Several different SAA proteins can form
amyloid deposits [12, 13]. The most common inflamma-
tory diseases that underlie AA amyloidosis in devel-
oped countries are rheumatoid arthritis, inflammatory
bowel disease, and familial Mediterranean fever (FMF),
an autosomal-recessive disorder now known to be due to
mutations in the gene encoding pyrin [14]. Chronic infec-
tions such as osteomyelitis, bronchiectasis, and tubercu-
losis still lead to the development of AA amyloidosis in
some parts of the world.
The distribution of organ involvement is somewhat
more restricted in AA amyloidosis than in AL disease.
Most patients with AA amyloidosis have renal involve-
ment. The liver, spleen, autonomic nervous system, and
thyroid also can be involved, but in contrast to AL amyloi-
dosis, cardiac involvement is rare. In general, AA amy-
loidosis progresses more slowly than does AL disease,
but the course is variable and tends to parallel that of the
underlying inflammatory condition [15, 16].
Familial amyloidosis
In the familial amyloidoses, a gene mutation inher-
ited in an autosomal-dominant manner results in a sin-
gle amino acid substitution that renders a plasma pro-
tein amyloidogenic. Mutations in the TTR gene are the
most common cause of familial amyloidosis. Approxi-
mately 100 TTR mutations have been identified. Most
of these mutations are amyloidogenic; however, several
mutations appear to be non-pathogenic [17]. A protec-
tive role of some of these non-amyloidogenic mutations
is suggested by the lack of amyloid disease in compound
heterozygous individuals who have inherited one TTR al-
lele with an amyloidogenic mutation and one allele with
a non-amyloidogenic mutation [17, 18]. Amyloidogenic
variants of apolipoprotein AI, apolipoprotein AII, fib-
rinogen A a–chain, lysozyme, gelsolin, and cystatin C un-
derlie less common forms of familial systemic amyloidosis
[1].
The clinical features of familial amyloidosis vary de-
pending on the underlying amyloidogenic protein and the
particular amino acid affected by the mutation. For exam-
ple, peripheral and autonomic neuropathy are the typical
manifestations in patients with the Val30Met TTR muta-
tion, while cardiomyopathy is the predominant manifes-
tation in individuals with the Val122Ile TTR mutation
[19].
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Fig. 1. Amyloid formation from precursor
protein to tissue deposit. Amyloid formation
begins with abnormal folding of a precursor
protein. Self-aggregation of the folding inter-
mediates leads to formation of protofilaments
with high beta pleated sheet content. Amy-
loid fibrils consist of 4 to 6 protofilaments
twisted around each other. Glycosaminogly-
cans and serum amyloid P component inter-
act with amyloid precursors and/or intact fib-
rils promoting fibrillogenesis and stabilizing
tissue deposits.
In senile systemic amyloidosis, wild-type TTR rather
than a mutated form of the protein forms amyloid de-
posits predominantly, but not exclusively, in the heart.
The disease tends to develop in elderly individuals and
can result in cardiomyopathy that usually is not as severe
or rapidly progressive as that associated with AL amyloi-
dosis [20].
Dialysis-related amyloidosis
Dialysis-related amyloidosis occurs as a result of depo-
sition of b-2 microglobulin amyloid in peri-articular tis-
sue and bone [21]. It typically occurs in patients who have
been dialysis-dependent for many years. b-2 microglobu-
lin is amyloidogenic when present at high concentrations
but not when present at physiologic concentrations. The
serum concentration of b-2 microglobulin is markedly in-
creased in patients with dialysis dependence because of
reduced clearance by the kidneys, and probably also be-
cause of increased production due to dialysis-associated
stimuli. Although a high concentration of b-2 microglob-
ulin appears to be required for the development of
dialysis-associated amyloidosis, other factors are likely
important, as most patients with elevated serum b-2 mi-
croglobulin levels do not develop disease, and the con-
centration of b-2 microglobulin does not correlate with
the severity of disease. Modification of b-2 microglobulin
by advanced glycation end products, oxidation, or other
constituents of the uremic environment might play a role
in amyloid fibril formation, but evidence for this is incon-
clusive [21–25].
Carpal tunnel syndrome, tenosynovitis, destructive
spondyloarthropathy, peri-articular soft tissue swelling,
bone fractures, and arthralgias involving the shoulders,
knees, wrists, and small joints of the hands are the typi-
cal clinical manifestations of dialysis-related amyloidosis.
b-2 microglobulin amyloid deposits also have been iden-
tified in the gastrointestinal tract, heart, and blood vessels
of patients with dialysis dependence, but the occurrence
of clinically evident extra-articular disease is rare [26].
Fibril formation and tissue deposition
The process of amyloid fibril formation begins with
abnormal folding of a protein that is normally solu-
ble (Fig. 1). The abnormal folding can result from a
single amino acid mutation, from a proteolytic cleav-
age event, or from intrinsic properties that only be-
come pathogenetically significant when the protein is
present in high concentrations or in the presence of
specific local environmental factors [27, 28]. The abnor-
mally folded intermediates aggregate into contiguous
beta sheet polypeptide chains that form protofilaments
with no appreciable likeness to the original precursor
protein. An amyloid fibril is comprised of four to six of
these protofilaments twisted around each other. One of
the remarkable aspects of amyloidogenesis is that de-
spite the marked diversity in structure and function of
the amyloidogenic precursor proteins, amyloid fibrils are
morphologically indistinguishable. The electron micro-
scopic appearance and size of the fibrils, the x-ray diffrac-
tion pattern, the beta-pleated sheet configuration, and
the ordered intercalation of Congo red dye that confers
birefringence under polarized light are common to all
amyloid fibrils [28]. In addition, all types of amyloid de-
posits, irrespective of the fibril type, contain constituents
including serum amyloid P (SAP) protein, heparan sul-
fate proteoglycan, apolipoprotein E, laminin, and type
IV collagen [29, 30].
Local factors influence both amyloid fibril formation
and tissue deposition. The composition of basement
membranes or extracellular matrix can contribute to tar-
geting of amyloid to specific tissues. Glycosaminoglycan
(GAG) moieties of proteoglycans appear to promote
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fibrillogenesis by stabilizing or inducing conformational
changes in amyloidogenic precursors that favor fibril for-
mation, and by providing protection from proteolysis dur-
ing fibril formation and after tissue deposition [31–35].
Local pH can affect the relative stabilities of the abnormal
and normal conformations of the precursor protein and
thus favor or retard fibrillogenesis. Experimental mod-
els suggest that amyloid fibrils themselves act as “seeds”
within tissues, generating additional fibril formation by
promoting amyloidogenic conformational changes in the
soluble precursor protein [36].
Mechanisms underlying clinical disease
Two mechanisms have been proposed to explain organ
dysfunction in amyloidosis. The first, sometimes referred
to as the “amyloid hypothesis,” is the direct disruption
of tissue architecture and function by amyloid accumu-
lation. That large quantities of deposited amyloid would
have a deleterious impact on the surrounding tissue is eas-
ily appreciated from histologic examination of affected
organs. In the kidney, the mesangium often appears to be
essentially replaced with amyloid, and marked alterations
in the components of the glomerular basement mem-
brane are readily apparent by ultrastructural examina-
tion. In the heart, amyloid infiltration causes thickening
and stiffening of the ventricular wall; these changes result
in impaired diastolic filling and reduced stroke volume.
Several observations suggest that processes other than
displacement of normal structures also are important
contributors to the manifestations of amyloidosis [27].
Demonstrations of interactions between AA or TTR
amyloid fibrils and the receptor for advanced glycosy-
lation end products (RAGE), and induction of specific
signal transduction pathways by these interactions, sug-
gest that local cellular activation might contribute to the
pathogenesis of amyloidosis [37, 38]. Additionally, dis-
crepancies between structural findings and clinical out-
comes indicate that the amount of amyloid accumulation
does not fully account for disease manifestations. For
example, despite indistinguishable echocardiographic
features among patients with AL and TTR cardiac amy-
loidosis, the severity of heart failure and the cardiac
mortality rate are substantially greater in AL compared
with TTR disease [39]. Direct toxicity of amyloidogenic
precursor proteins is suggested by findings that cellu-
lar oxidant stress is increased and that contractility and
relaxation are impaired when cultured cardiomyocytes
are exposed to amyloidogenic light chains [40]. Similarly,
TTR folding intermediates and aggregates are cytotoxic
in vitro [41, 42], and TTR aggregates have been detected
in neuronal tissue in the absence of amyloid in patients
with amyloidogenic TTR mutations [42]. The functional
significance of the non-fibrillar TTR deposits in these pa-
tients is not clear. However, the possibility that precursor
Table 2. Treatment targets for the systemic amyloidoses
Treatment target Treatment approach Treatment status
Precursor protein Anti-plasma cell In use: AL
production or chemotherapy
concentration
Anti-inflammatory In use: AA
agents
Liver transplantation In use: Familial
Renal transplantation In use: DRA
Hemofiltration or In use: DRA
adsorption
Fibril formation GAG mimetics Human studies: AA
TTR stabilizers Human studies: Familial
Amyloid deposits GAG mimetics Human studies: AA
IDOX Human studies: AL
SAP depletion Human studies: AL
Abbreviations are: AL, amyloid light chain disease; AA, amyloid A
disease, DRA, dialysis-related amyloidosis; GAG, glycosaminoglycan; TTR,
transthyretin; IDOX, 4′-iodo-4′-deoxy-doxorubicin; SAP, serum amyloid P.
proteins and/or their folding intermediates are toxic has
important implications for treatment strategies. Demon-
strations that several amyloidogenic proteins are capable
of forming ion-permeable channels have led to the hy-
pothesis that channel formation in cell membranes un-
derlies the cytotoxicity [43].
Treatment targets
Each of the steps in the pathway from precursor pro-
tein to amyloid deposition is a potential target for treat-
ment of the amyloidoses. Substantial progress has been
made during the past several years in the design of new
therapeutic approaches based on several of these targets
(Table 2).
Target 1: Precursor protein production. Reducing the
production of the amyloidogenic precursor protein is the
mechanism of most treatments currently used in clinical
practice. For AL amyloidosis, chemotherapeutic agents
with activity against plasma cells, the source of the amy-
loidogenic light chains, have been used for the past several
decades. The conventional approach, adopted from expe-
rience in treating multiple myeloma, is to administer mul-
tiple cycles of oral melphalan and prednisone. Although
the efficacy of this treatment has been demonstrated in
two randomized trials, the impact is modest. A hemato-
logic complete response (CR), defined as normalization
of the bone marrow and disappearance of monoclonal
light chain from the blood and urine, occurs in fewer than
5% of individuals, and median survival is increased from
7 to 8 months to only 12 to 18 months [9, 10].
A more aggressive approach that also targets the
source of the amyloidogenic protein is to administer
melphalan intravenously at a myelo-ablative dose (140–
200 mg/m2) and follow the chemotherapy with autolo-
gous stem cell transplantation to facilitate bone marrow
recovery [3]. The experience with this treatment has
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GAG mimetic Fig. 2. Prevention of amyloid fibril forma-tion by GAG mimetics. GAG mimetics
are small molecules that compete with gly-
cosaminoglycans (GAGs) for interaction with
amyloidogenic precursors and fibrils and
thereby inhibit fibril formation and tissue de-
position.
been reported in nonrandomized studies from several
centers [2, 44, 45]. In the largest of these series, treat-
ment with high-dose melphalan and stem cell transplan-
tation (HDM/SCT) was initiated in 312 patients [2]. The
hematologic CR rate evaluated one year after treatment
was 40%, and median survival was 4.6 years. Treatment-
associated mortality, 13%, was higher than that typically
seen when high-dose chemotherapy regimens are used
for malignancies; this increased mortality rate reflects, in
large part, the impact of underlying organ dysfunction on
treatment-associated toxicity.
An important finding from the HDM/SCT experience
is that improvements in function of affected organs can
occur in AL amyloidosis, and that the improvements
are much more likely in the patients who achieve a
hematologic CR. For example, among patients with re-
nal involvement, a hematologic CR was associated with
a reduction in urinary protein excretion from a mean
of 9.6 g/day prior to treatment to a mean of 1.6 g/day
12 months after treatment. In contrast, urinary protein
excretion was unchanged in patients with persistence of
plasma cell dyscrasia [46]. This observation, as well as sim-
ilar findings in other organ systems [2], indicates that, de-
spite pre-existing amyloid deposits, functional improve-
ments are possible if new amyloid production is halted.
The current therapeutic approach for AA amyloidosis
is treating the underlying inflammatory disease, thereby
reducing production of SAA by the liver. In FMF, de-
velopment of AA amyloidosis can be prevented in most
patients by the administration of colchicine, which effec-
tively inhibits FMF-associated inflammation, probably
by inhibiting neutrophil chemotaxis and adhesion [47].
However, for many patients with other underlying dis-
eases, adequate suppression of inflammation cannot be
achieved with current anti-inflammatory and immuno-
suppressive agents, and SAA production and AA fibril
formation persist.
Orthotopic liver transplantation has been used for
approximately 15 years to eliminate the source of the
amyloidogenic protein in familial TTR amyloidosis. This
approach is now considered the definitive treatment for
this disease [48–51]. Despite the synthesis of some TTR
by the choroid plexus, mutant TTR disappears from
the circulation after transplantation and neuropathy im-
proves. Because wild-type TTR can deposit as amyloid
at sites of pre-existing amyloid deposits, cardiac disease
can continue to progress after liver transplantation, par-
ticularly if the pre-transplant amyloid burden is high [52].
Optimal timing of liver transplantation can be difficult to
determine, but knowing the rate of progression of dis-
ease in other affected family members and the particu-
lar TTR mutation can help inform such decisions. Liver
transplantation has been used to treat other types of fa-
milial amyloidosis as well, but the experience is largest
for TTR disease [53].
Current treatments for dialysis-related amyloidosis
aim to enhance b-2 microglobulin clearance and thereby
decrease the concentration of the circulating amyloido-
genic precursor protein. The most effective treatment for
dialysis-associated amyloidosis is renal transplantation.
Restoration of renal function increases b-2 microglob-
ulin clearance and also might reduce b-2 microglobulin
production. In the absence of renal transplantation, clear-
ance of b-2 microglobulin can be enhanced with high-
flux dialyzers or with hemodiafiltration. The use of a b-2
microglobulin adsorption column placed in series with a
high-flux dialyzer has resulted in symptomatic improve-
ment in small studies of patients with dialysis-related
amyloidosis [54, 55].
Target 2: Fibril formation. Two approaches currently
under investigation for inhibiting amyloid fibril forma-
tion will be reviewed. The first approach is the use of a
GAG mimetic to prevent AA amyloid fibril formation.
The second is the use of small molecules to stabilize TTR
in its tetrameric conformation and thereby inhibit the for-
mation of the folding intermediates that ultimately aggre-
gate into amyloid fibrils.
Glycosaminoglycans such as heparan sulfate and chon-
droitin sulfate are constituents of amyloid deposits. A
growing body of evidence suggests that these sulfated
GAGs contribute to amyloidogenesis by binding to pre-
cursor proteins and inducing conformational changes re-
quired for fibril assembly, and by stabilizing amyloid
fibrils (Fig. 2) [56–58]. Low-molecular-weight compounds
that compete with sulfated GAGs for binding to the
amyloidogenic protein have been identified as potential
therapeutic agents [59–61]. A small, highly charged sul-
fonated molecule, NC-503 (1,3-propanedisulfonic acid,
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Fig. 3. Stabilization of TTR tetramer as a
strategy to inhibit amyloid formation. TTR
exists as a homo-tetramer with two ligand
binding sites. Because amyloidogenic muta-
tions favor monomer formation, and amy-
loid forms from monomers but not tetramers,
molecules that stabilize TTR in its tetrameric
configuration should prevent formation of
folding intermediates and ultimately amyloid
fibrils.
disodium salt), was designed specifically to inhibit the
binding of sulfated GAG to amyloidogenic precursors.
Anti-amyloidogenic activity of orally administered NC-
503 has been demonstrated in murine models of AA amy-
loidosis. In these studies, NC-503 reduced splenic amyloid
deposition in a dose-dependent fashion [62]. NC-503 is
currently being studied as a treatment for AA amyloi-
dosis in a multicenter international Phase II/III placebo-
controlled trial. A second GAG mimetic that targets Ab
amyloid fibril formation is being studied in patients with
Alzheimer’s disease [63].
Human TTR functions as a transport protein for
thyroxine and retinol-binding protein. The protein ex-
ists as a tetramer with four identical subunits and two
ligand-binding sites located at the interface of the two
dimers. TTR amyloid fibrils arise from the monomeric,
but not the tetrameric, configuration. Amyloidogenic
TTR mutations appear to destabilize the tetrameric con-
figuration and facilitate monomer formation [64]. In
contrast, binding of thyroid hormones and their deriva-
tives stabilizes the tetrameric form of TTR. That is,
occupation of the TTR binding site inhibits tetramer
dissociation into monomers and thereby inhibits fibril
formation by amyloidogenic TTR variants (Fig. 3) [65].
This tetramer-stabilizing effect of binding site occupation
has led to efforts at identifying other tetramer-stabilizing
molecules that could be administered therapeutically
to prevent amyloid formation. Using functional screens
and structure-based approaches, several such molecules
have been identified including several nonsteroidal anti-
inflammatory drugs (NSAIDs) [66–68]. Multicenter clin-
ical trials using tetramer stabilizers are currently being
planned. If effective at inhibiting amyloid fibril forma-
tion, treatment with stabilizers of the native TTR con-
formation could prevent the development of amyloid
disease in individuals with known amyloidogenic muta-
tions. In addition, stabilization of the TTR tetramer could
be of value even after orthotopic liver transplantation be-
cause of the amyloidogenic potential of wild-type TTR
in the presence of existing amyloid deposits. Although
the TTR protein, with its ligand binding sites, might be
ideally suited to the identification of “conformation sta-
bilizers,” this strategy of structure-based identification of
stabilizing molecules also might be applicable to other
amyloidogenic precursor proteins.
Target 3: Amyloid deposits. Amyloid deposits are rel-
atively resistant to proteolysis. Evidence for regression
of tissue amyloid by endogenous mechanisms comes pri-
marily from demonstrations of functional improvements
in affected organs and reductions in tissue uptake of
radiolabeled SAP protein following treatment-induced
cessation of amyloid precursor protein production [46,
69–72]. For example, uptake of radiolabeled SAP into
affected organs is decreased in patients with AL amyloi-
dosis following high-dose chemotherapy that has eradi-
cated the plasma cell dyscrasia, and in patients with TTR
familial amyloidosis following orthotopic liver transplan-
tation. The clinical improvements and SAP scan results
have been interpreted as evidence that amyloid deposits
can be degraded once new amyloid deposition ceases [72,
73]. However, these demonstrations provide only indirect
support for amyloid regression by endogenous mecha-
nisms, and histologic confirmation is relatively scant.
Several interventions aimed at facilitating amyloid
degradation are under investigation. The GAG mimetics
are thought to not only inhibit amyloid fibril formation
but also to destabilize tissue amyloid deposits and thereby
promote their removal [59, 74]. Like GAG mimetics, in-
hibitors of heparan sulfate biosynthesis reduce amyloid
deposition in vitro and in vivo and might have poten-
tial application as therapeutic agents [75]. An iodinated
derivative of doxorubicin, 4′-iodo-4′-deoxydoxorubucin
(IDOX), binds with high affinity to amyloid fibrils and
promotes their disaggregation in vitro and in vivo in ex-
perimentally induced murine AA amyloidosis [76–78].
Administration of IDOX to patients with AL amyloidosis
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showed promising results in a small, uncontrolled series,
but its efficacy was not demonstrated in a larger multi-
center trial [79, 80].
Disruption of the interaction between SAP and
amyloid is another approach being investigated as a
degradation-promoting treatment. Because SAP com-
ponent is present in all types of amyloid deposits, tar-
geting the SAP-amyloid interaction could have broad
application [81]. SAP itself is highly resistant to prote-
olysis, and binding of SAP to amyloid fibrils protects
them from proteolysis in vitro [82]. SAP exists in a
dynamic equilibrium between the circulation, where it
is unbound, and tissue, where it is bound to amyloid.
Pepys et al hypothesized that removal of circulating
SAP would drive SAP from tissue amyloid to the cir-
culation and render the tissue amyloid less resistant to
proteolysis [83]. R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-
oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), a
palindromic compound that binds with high affinity to
SAP, cross-links two SAP molecules together in a man-
ner that occludes the binding surface of SAP. CPHPC ad-
ministration depleted SAP from the circulation and from
amyloid deposits in murine models, and studies in humans
demonstrated rapid SAP clearance from the circulation
[83]. However, the impact of CPHPC administration on
amyloid deposits in either animal models or in humans is
not known.
Substantial progress in understanding the mechanisms
of amyloid fibril formation and tissue deposition has en-
abled development of novel treatment approaches for
the progressive, and often fatal, systemic amyloidoses.
Despite the wide variety of amyloidogenic precursor pro-
teins, the commonalities in the processes of fibril forma-
tion and biochemical composition of amyloid deposits
should allow application of several of these treatment
strategies to multiple types of amyloid disease. Although
the systemic amyloidoses are rare diseases, the advances
described in this Forum might have important implica-
tions for more common localized forms of amyloid depo-
sition such as that occurring in Alzheimer’s disease.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chairman, Department of
Medicine, Caritas St. Elizabeth’s Medical Center, Boston,
Massachusetts): How much do we know about the pos-
sible resorption of amyloid from the kidney, especially
in the context of chronic kidney disease, in which fac-
tors that inhibit proteolysis also might be present? Does
the decrease in proteinuria experienced by patients fol-
lowing high-dose melphalan and stem cell engraftment
reflect decreased amyloid deposition and kidney repara-
tion as determined by SAP scintigraphy or repeat kidney
biopsy?
DR. DEMBER: Resistance to proteolysis is a feature of
amyloid. Demonstrations of reductions in SAP uptake
in the kidney and other organs when new amyloid pro-
duction is halted by treatment have been interpreted as
evidence for degradation of existing tissue amyloid de-
posits by endogenous mechanisms [70–72]. However, I
would view the SAP scintigraphy findings as suggestive
but not definitive evidence for amyloid degradation. It is
not known whether amyloid that has been incorporated
into tissue for long periods binds SAP in the same manner
as newly deposited amyloid. It is possible that the changes
observed in SAP scans before and after treatment reflect
changes in interactions between SAP and amyloid rather
than changes in tissue amyloid content. Very few histo-
logic studies have addressed this issue, probably because
of the invasive nature of the procedures required to ob-
tain tissue. In a small case series, post-treatment renal
biopsies from two patients with AL amyloidosis did not
show reductions in tissue amyloid by Congo red stain-
ing compared with pretreatment biopsies despite near
resolution of proteinuria [84]. Abdominal fat aspirates
performed annually in our large cohort of patients with
AL amyloidosis do not suggest that there is substantial
amyloid resorption from fat tissue following eradication
of the plasma cell dyscrasia. The marked reductions in
proteinuria observed in AL amyloidosis after amyloid
production is halted could reflect amyloid regression, but
alternatively might be the result of elimination of a direct
toxic effect on the glomerulus of fresh amyloid, amyloido-
genic light chains, cytokines, or other mediators.
DR. MADIAS: Is any information available on relapse
of the plasma cell clone in AL amyloidosis?
DR. DEMBER: The relapse rate for AL amyloidosis fol-
lowing high-dose chemotherapy appears to be substan-
tially lower than that for multiple myeloma. We found
that 6 of 73 patients (8%) with a complete hematologic
response one year after treatment with high-dose mel-
phalan and autologous stem cell transplant had a relapse
of the plasma cell dyscrasia at two years. Relapses be-
yond two years were not observed [2]. In contrast, nearly
all patients with multiple myeloma eventually relapse.
DR. MADIAS: Has this treatment been used for light-
chain deposition disease?
DR. DEMBER: Yes. Bruno Royer and colleagues pub-
lished a series of 11 patients with light- or heavy-chain
deposition disease treated with high-dose chemotherapy
and autologous stem cell transplantation [85]. The initial
four patients received three to six monthly courses of cy-
toreductive chemotherapy (vincristine, doxorubicin, and
methylprednisolone) prior to treatment with either com-
bination chemotherapy (melphalan, cyclophosphamide,
CCNU, VP16) and total-body irradiation, or melpha-
lan and busulfan. The subsequent seven patients were
treated with high-dose intravenous melphalan alone at
doses similar to those used for AL amyloidosis. Six of the
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11 patients achieved a complete hematologic response,
and several patients had improvement in affected or-
gan function. A marked reduction in proteinuria was ob-
served in four of the patients following treatment.
At Boston University we are using high-dose mel-
phalan with autologous stem cell transplantation for
light-chain deposition disease (LCDD) as well. Although
LCDD is less rapidly progressive and associated with
a lower mortality rate compared with AL amyloidosis,
extrarenal involvement is common, and thus aggressive
treatment might be warranted, not only to prevent renal
failure but also for cardiac, liver, or lung disease.
DR. JOHN T. HARRINGTON (Dean Emeritus, Tufts Uni-
versity School of Medicine; Division of Nephrology, Tufts-
New England Medical Center, Boston, Massachusetts):
When you spoke about the familial forms of amyloido-
sis and mentioned TTR as the most frequent type, you
said that a number of other proteins could be similarly
amyloidogenic. But I believe you also said that some of
these proteins could be protective. Could you clarify that
point?
DR. DEMBER: I was referring to what appears to be an
anti-amyloidogenic effect of certain amino acid substitu-
tions in the TTR protein. More than 100 mutations have
been identified in the TTR gene. Most of these mutations
render the TTR protein amyloidogenic. However, many
of the mutations do not confer amylodogenic properties
to the protein product. That is, under in vitro conditions,
the TTR protein with a non-pathogenic mutation is no
more likely to form amyloid fibrils than is wild-type TTR,
and families that carry such mutations do not develop
amyloidosis. Interestingly, a few of the mutations that
have been identified appear to inhibit TTR amyloidoge-
nesis. Under in vitro amyloid-promoting conditions, the
TTR protein with these “protective” amino acid substitu-
tions is less prone to amyloid formation than is wild-type
TTR, and individuals who have inherited one allele with
an amyloidogenic mutation and one allele with a “protec-
tive” mutation do not develop amyloidosis, unlike their
family members who have one allele with the amyloido-
genic mutation and one allele with the wild-type TTR
gene. It appears from physicochemical studies that the
protective amino acid substitution confers stability to the
tetrameric configuration of TTR [18].
DR. RONALD D. PERRONE (Division of Nephrology,
Tufts-New England Medical Center): Do you envision any
new diagnostic tests? Are there any new serologic, imag-
ing, or urine tests that might be helpful?
DR. DEMBER: The diagnosis of amyloidosis requires
histologic demonstration of Congo red binding with bire-
fringence under polarized light. At present, there are not
alternatives to tissue examination with adequate speci-
ficity for making the diagnosis of amyloidosis. Determi-
nation of the type of amyloidosis requires the use of a
variety of tests, including immunofixation electrophore-
sis of serum and urine, and bone marrow biopsy to look
for evidence of a plasma cell dyscrasia; immunohisto-
chemistry to identify specific proteins in tissue amyloid
deposits; isoelectric focusing of serum proteins to iden-
tify abnormal TTR proteins; and DNA analysis to identify
mutations in genes encoding TTR or other amyloidogenic
proteins. For AL amyloidosis, the quantitative free light
chain assay is a new test that appears to have utility both
for diagnosis and in following the response to treatment
directed against the clonal plasma cells [86]. This nephelo-
metric assay measures free kappa and lambda light chains
in the circulation or urine and provides a measure that is
more quantitative than immunofixation electrophoresis.
Because light chain excretion is dependent on GFR, it is
the ratio of kappa and lambda light chains rather than
their absolute concentrations that is the relevant mea-
sure in patients with renal impairment. As I mentioned
earlier, radiolabeled SAP has been used to image tissue
amyloid and follow disease progression. However, this
methodology is not widely available for use in clinical
practice.
DR. PERRONE: I have a patient, approximately
1.5 years post second deceased-donor kidney transplant,
and 15 years post first deceased-donor transplant, who
developed macroglossia and has AL amyloidosis. He is
receiving standard immunosuppressive therapy for the
kidney transplant with mycophenolate, cyclosporine, and
prednisone, and he has excellent allograft function. Is he
a candidate for high-dose chemotherapy with stem cell
transplantation?
DR. DEMBER: I’d be interested in knowing whether AL
amyloidosis was the cause of his native kidney failure.
If so, his survival for 15 years without treatment of the
plasma cell disease would be unusual.
DR. PERRONE: The cause is unknown, as the initial
diagnosis was made in China.
DR. DEMBER: We have used high-dose melphalan with
autologous stem cell transplant as treatment for two pa-
tients with AL amyloidosis and prior kidney transplants
and one patient with LCDD and prior kidney transplant.
In addition, there is a growing experience with the ad-
ministration of high-dose chemotherapy and stem cell
transplantation following heart transplant for patients
with AL amyloidosis and cardiac involvement when the
heart disease is severe enough to preclude initial aggres-
sive anti-plasma cell therapy. Our approach in patients
with renal allografts has been to continue giving cal-
cineurin inhibitors and glucocorticoids throughout the
peri-stem-cell-transplant period but to temporarily dis-
continue agents such as mycophenolate or azathioprine
that have effects on the bone marrow and could interfere
with marrow recovery. In addition, we have used cy-
clophosphamide rather than G-CSF as the stem cell mo-
bilizing agent in these patients because of concern that the
high doses of G-CSF required will trigger acute allograft
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rejection. One of our three renal transplant patients had
an episode of steroid-responsive acute renal allograft re-
jection that occurred approximately four months follow-
ing stem cell infusion and might have been the conse-
quence of immune cell recovery.
The patient you describe has macroglossia, which sug-
gests soft tissue involvement. Is there any evidence of
organ disease?
DR. PERRONE: He appears to have cardiac involve-
ment with congestive heart failure.
DR. DEMBER: I asked this question because one could
argue that soft tissue involvement alone is not an indi-
cation for treating with high-dose chemotherapy, but if
cardiac or other organ involvement is present, aggressive
treatment is warranted.
DR. MADIAS: Can you summarize any results of
other organ function, namely liver, heart, and auto-
nomic nervous system, following high-dose melphalan
and autologous stem cell transplant and a hematologic
response?
DR. DEMBER: Clinical improvements occur in all these
organ systems following aggressive treatment and are
more likely among patients who achieve a hematologic
complete response. In our series of 312 patients with
AL amyloidosis, clinical improvement in liver disease at
1 year, defined as a reduction in liver span of 2 cm or
greater among those with hepatomegaly prior to treat-
ment or a reduction in serum alkaline phosphatase con-
centration of 50% or greater, was seen in approximately
50% of patients with a hematologic complete response.
Cardiac improvement at 1 year, defined as a reduction
in intraventricular septal thickness of 2 mm or greater
if it was abnormal prior to treatment or improvement
in congestive heart failure based upon the New York
Heart Association classification, was observed in 27%
of patients with a hematologic complete response [2].
Autonomic nervous system dysfunction is more likely to
reverse than is peripheral neuropathy; however marked
improvement in sensory neuropathy has been observed
following treatment in some patients. Also, in addition
to clinical measures of organ function, improvements in
both performance status as assessed by the Southwestern
Oncology Group scale and quality-of-life as measured by
the SF-36 questionnaire have been demonstrated among
patients achieving a hematologic response [87].
DR. HARRINGTON: What is the normal role of SAP?
When it is depleted by CPHPC, what happens to the pa-
tients?
DR. DEMBER: SAP is a member of the pentraxin
family of proteins that includes C-reactive protein. Hu-
man SAP is synthesized by the liver and consists of five
non-covalently associated identical subunits that form a
disk-like structure. In addition to binding to all types of
amyloid fibrils, SAP binds to DNA and chromatin in a
calcium-dependent manner. The normal role of SAP is
not fully elucidated, but it is believed to contribute to in-
nate immunity, and recent studies suggest that SAP binds
to apoptotic cells and facilitates phagocytosis of apop-
totic bodies by macrophages [88]. Interestingly, the SAP
knockout mouse develops an immune complex glomeru-
lonephritis with auto-antibodies directed against DNA,
chromatin, and histones. However, it is not clear that
the development of auto-immunity in the SAP knock-
out mice is the result of SAP deficiency rather than an
effect attributable to the genetic background of the mice,
as the phenotype appears to be strain-dependent [89].
Of note, the SAP knockout mice have a normal lifespan.
The impact of SAP depletion in humans is not known.
The published experience with CPHPC administration is
limited to small numbers of individuals, and the treatment
duration was short.
DR. HARRINGTON: More than 30 years ago, Alan
Cohen, John Mannick, and I published a paper about the
first two patients with amyloidosis who received renal
transplants [90]. Does your group have a series of long-
term amyloid renal transplant survivors? What happens
to them 15 to 20 years later?
DR. DEMBER: Most of the published literature on kid-
ney transplantation in amyloidosis is in patients with
AA amyloidosis. At most centers, patients with AL amy-
loidosis are not considered candidates for renal trans-
plantation unless the underlying plasma cell dyscrasia is
eradicated. Anthony Bleyer and colleagues reported re-
nal allograft and patient survival according to the under-
lying renal disease using UNOS registry data and found
that one-year and three-year allograft survival for pa-
tients with amyloidosis were 79.5% and 71.1%, respec-
tively. Patient survival at one and three years was 87.1%
and 79.3%, respectively. When compared with other
causes of underlying renal failure, amyloidosis ranked
30/33 and 32/33 for allograft survival and patient sur-
vival, respectively, suggesting that outcomes are worse
for this disease than for nearly all other underlying con-
ditions leading to kidney transplantation [91]. Of note,
fewer than 100 individuals with amyloidosis were identi-
fied in the UNOS registry during a 9-year period, reflect-
ing the small numbers of patients with this disease who
undergo renal transplantation. The published experience
describing long-term outcomes is limited to case reports
or very small case series. Because it is likely that most
of the patients in existing databases received renal trans-
plants while there was amyloid production ongoing, the
findings of studies such as that by Bleyer et al probably
are not applicable to patients who have treatment that
fully eradicates new amyloid production.
DR. ANDREW S. LEVEY (Division of Nephrology,
Tufts-New England Medical Center): What has been the
experience in people with beta-2 microglobulin disease
who receive a kidney transplant? Does the disease go
away?
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DR. DEMBER: Renal transplantation is the most ef-
fective treatment for beta-2 microglobulin amyloidosis.
Substantial improvement in pain is typical very soon after
transplantation, and presumably new amyloid deposition
ceases with restoration of renal function. However, it is
not clear whether there is regression of existing amyloid
deposits. Uptake of radiolabeled SAP decreased in 8 of 9
patients who received transplants [92]; however, several
studies found no evidence of radiographic resolution of
bone cysts or histologic regression of amyloid many years
after transplantation.
DR. ANNAMARIA KAUSZ (Division of Nephrology,
Tufts-New England Medical Center): Were the dismal
outcomes you presented in AL amyloidosis prior to rou-
tine stem cell transplantation? Is aggressive treatment
with high-dose melphalan and stem cell transplantation
becoming widely accepted as standard of care? Also,
given that organ deposition of amyloid might not reverse
following this treatment, do you envision a two-pronged
approach in the future, whereby individuals undergo
HDM/SCT, and receive a product to reduce fibril for-
mation or degrade amyloid deposits?
DR. DEMBER: The use of high-dose melphalan and
stem cell transplantation for AL amyloidosis has become
more widespread over the past several years, and is be-
coming accepted as the best available treatment for the
disease for selected patients. The recent decision by the
Centers for Medicare and Medicaid Services (CMS) to
expand Medicare coverage of autologous stem cell trans-
plantation to include AL amyloidosis is a reflection of the
acceptance of this treatment by CMS and professional
societies. Challenges remain in modifying the treatment
to reduce toxicity, which is substantial in these patients
because of underlying organ dysfunction, in identifying
the most appropriate candidates for treatment, and in de-
veloping anti-plasma cell therapies for patients who are
too ill to undergo high-dose chemotherapy or who have
persistent plasma cell disease after such treatment.
I believe that a multi-pronged approach will be ap-
plied in the future not only for AL amyloidosis but for
the other systemic amyloidoses as well. In the example
of AL amyloidosis, treatments directed at amyloid fibril
formation or tissue amyloid deposits could be particularly
valuable for patients who either do not achieve a hemato-
logic complete response with high-dose chemotherapy or
have persistent organ dysfunction despite a good hema-
tologic response.
DR. MADIAS: As an extension to Annamaria’s ques-
tion, given the high mortality rate associated with the
stem cell transplantation procedure, could you please ex-
pand on the timing of intervention? Also, what factors
predict success?
DR. DEMBER: For AL amyloidosis, treating early in
the course of the disease is desirable. While there is no
evidence that early treatment is associated with greater
chemo-responsiveness of the clonal plasma cells, there
are advantages with respect to tolerance of the treatment
and reversibility of organ dysfunction. In general, the tox-
icities associated with high-dose chemotherapy increase
with the degree of organ dysfunction, and if organ dys-
function is of sufficient severity, treatment toxicities can
preclude aggressive treatment. This is particularly rele-
vant with cardiac involvement, as stem cell mobilization
and collection are particularly challenging for patients
with severe cardiac amyloid disease. The overall perfor-
mance status of the patient also predicts treatment toler-
ance. And with respect to organ dysfunction, reversibility
becomes less likely with greater degrees of organ dysfunc-
tion. Clear predictors of hematologic response to high-
dose chemotherapy have not been identified.
DR. LEVEY: Why is AL amyloidosis so responsive
to high-dose chemotherapy and transplantation when
myeloma is not? I thought that hematologic malignan-
cies with faster cell growth and a larger tumor burden
have a better response to the chemotherapy.
DR. DEMBER: The difference in responsiveness be-
tween these two diseases is probably a function of the
difference in plasma cell burden. As you point out, the
plasma cell burden is substantially greater in multiple
myeloma than in AL amyloidosis. Thus, there is a greater
likelihood in multiple myeloma that not all clonal plasma
cells will be eradicated by the chemotherapy. The in-
creased plasma cell burden in multiple myeloma also in-
creases the likelihood that the stem cells harvested prior
to dose-intensive chemotherapy will be contaminated
with clonal plasma cells that will ultimately engraft. To re-
duce the plasma cell burden prior to stem cell harvesting,
cytoreductive therapy with multiple cycles of combina-
tion chemotherapy is generally administered to patients
with multiple myeloma, and stem cell mobilization in such
patients is usually performed with a cytotoxic agent such
as cyclophosphamide rather than G-CSF. However, de-
spite these measures, the number of clonal plasma cells
at the time of stem cell harvesting and melphalan admin-
istration is still greater in multiple myeloma than in AL
amyloidosis.
DR. KAUSZ: Is anything known about the potential tox-
icities of the investigational agents that reduce fibril for-
mation or degrade amyloid deposits?
DR. DEMBER: NC-503, the GAG mimetic that inhibits
AA amyloid fibril formation and promotes fibril degrada-
tion, is currently in clinical trials. Information should be
available about both its effectiveness and toxicity within
the next several months. In early-phase trials involving
healthy individuals, the drug was well-tolerated without
apparent toxicity, but the treatment duration was brief
[62]. We all are familiar with the toxicities of NSAIDs,
agents that are being investigated as TTR tetramer stabi-
lizers. Whether reduced availability of TTR for binding to
its natural ligands will have clinically important effects is
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not known, but this is not a major concern because TTR
functions as a “back-up” transporter of thyroxine and
retinol-binding protein. The main toxicity of IDOX, the
doxorubucin derivative that binds to all types of amyloid
and is thought to promote clearance of deposits, is gran-
ulocytopenia. Cardiotoxicity, a concern with this agent as
with other anthracyclines, was not apparent in small tri-
als. In the report describing CHPHC administration to a
small number of patients with amyloidosis, toxicity was
not observed [83]. It must be noted that the published
experience with each of these agents is limited to uncon-
trolled studies with small numbers of patients, and the
findings regarding toxicity must be viewed as preliminary.
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